Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0R4OM
|
|||
| Former ID |
DAP000034
|
|||
| Drug Name |
Trifluoperazine
|
|||
| Synonyms |
Calmazine; Eskazine; Fluoperazine; Flurazine; Modalina; Stelazine; Stellazine; TFP; Trifluoperazin; Trifluoperazina; Trifluoperazinum; Trifluoromethylperazine; Trifluoroperazine; Trifluperazine; Triflurin; Trifluroperizine; Triftazin; Triftazine; Triperazine; Triphtazin; Triphtazine; Triphthasine; PMS Trifluoperazine; Stelazine Concentrate; Trifluoperazina [Italian]; Trifluoperazine HCl; Trifluoperazine dihydrochloride; Trifluoroperazine dihydrochloride; Tripfluoperazine Hydrochloride; NCI17474; RP 7623; SKF 5019; Apo-Trifluoperazine; Eskazine (TN); Eskazinyl (TN); Jatroneural (TN); Modalina (TN); Novo-Trifluzine; Stelazine (TN); Terfluzine (TN); Trifluoperaz (TN); Trifluoperazina [INN-Spanish]; Trifluoperazine (INN); Trifluoperazine [INN:BAN]; Trifluoperazinum [INN-Latin]; Apo-trifluoperazine (TN); Stelazine (*Dihydrochloride*); Trifluoromethyl-10-(3'-(1-methyl-4-piperazinyl)propyl)phenothiazine; 10-(3-(4-Methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)phenothiazine; 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)-10H-phenothiazine; 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)-phenothiazine; 10-(gamma-(N'-Methylpiperazino)propyl)-2-trifluoromethylphenothiazine; 10-[3-(4-METHYL-PIPERAZIN-1-YL)-PROPYL]-2-TRIFLUOROMETHYL-10H-PHENOTHIAZINE; 10-[3-(4-Methyl-1-piperazinyl)propyl]-2-(trifluoromethyl)-10H-phenothiazine; 10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)-10H-phenothiazine; 10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)phenothiazine; 10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)phenothiazine dihydrochloride; 2-Trifluoromethyl-10-(3'-(1-methyl-4-piperazinyl)propyl)phenothiazine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Schizophrenia [ICD-11: 6A20; ICD-10: F20] | Approved | [1] | |
| Therapeutic Class |
Antipsychotic Agents
|
|||
| Company |
GlaxoSmithKline plc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H24F3N3S
|
|||
| Canonical SMILES |
CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F
|
|||
| InChI |
1S/C21H24F3N3S/c1-25-11-13-26(14-12-25)9-4-10-27-17-5-2-3-6-19(17)28-20-8-7-16(15-18(20)27)21(22,23)24/h2-3,5-8,15H,4,9-14H2,1H3
|
|||
| InChIKey |
ZEWQUBUPAILYHI-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 117-89-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9377, 602753, 841996, 4252673, 5664287, 7890752, 7980830, 10319712, 10505141, 11110644, 11110645, 11120338, 11120826, 11121314, 11121780, 11122260, 11336018, 11361257, 11362944, 11363562, 11364843, 11365506, 11366124, 11367405, 11368068, 11368686, 11369967, 11371059, 11371060, 11372247, 11373007, 11373669, 11373974, 11375567, 11376230, 11376848, 11378135, 11405822, 11408478, 11458546, 11460495, 11462229, 11466341, 11467461, 11484491, 11486261, 11488644, 11491189, 11492183, 11494482
|
|||
| ChEBI ID |
CHEBI:45951
|
|||
| ADReCS Drug ID | BADD_D02281 ; BADD_D02282 | |||
| SuperDrug ATC ID |
N05AB06
|
|||
| SuperDrug CAS ID |
cas=000117895
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Parabacteroides distasonis
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Parabacteroides distasonis was decreased by Trifluoperazine dihydrochloride (adjusted p-values: 1.62E-03). | |||
|
Studied Microbe: Prevotella copri
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Prevotella copri was decreased by Trifluoperazine dihydrochloride (adjusted p-values: 7.47E-04). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Eubacterium eligens
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Eubacterium eligens was decreased by Trifluoperazine dihydrochloride (adjusted p-values: 7.67E-04). | |||
|
Studied Microbe: Eubacterium rectale
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Eubacterium rectale was decreased by Trifluoperazine dihydrochloride (adjusted p-values: 3.10E-03). | |||
|
Studied Microbe: Roseburia hominis
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Roseburia hominis was decreased by Trifluoperazine dihydrochloride (adjusted p-values: 3.60E-04). | |||
|
Studied Microbe: Roseburia intestinalis
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Roseburia intestinalis was decreased by Trifluoperazine dihydrochloride (adjusted p-values: 2.53E-03). | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 2 | Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018 Mar 29;555(7698):623-628. | |||
| REF 3 | Inhibitory effect of jujuboside A on glutamate-mediated excitatory signal pathway in hippocampus. Planta Med. 2003 Aug;69(8):692-5. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.